Lenacapavir: new drug for the treatment of multidrug-resistant HIV infection
Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci) · 01.01.2024
DOI: 10.14456/ijps.2024.7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci), erschienen am 01.01.2024. Verfasst von Chatchai Wararit.
Abstract (Originalsprache)
HIV infection is currently still an epidemic disease which affect quality of life and life expectancy. Currently, there were reports of the antiretroviral drug resistance incidence. Lenacapavir is a novel drug in capsid inhibitors approved for treatment multidrug-resistant HIV infection in combination with optimized background regimen. Lenacapavir is available as an oral and subcutaneous injection used for initiation treatment. Subcutaneous injection drug has a half-life of 8-12 weeks used for maintenance treatment and administered via subcutaneous every 6 months. Clinical trial data supports efficacy for viral suppression and increase the CD4+ cell count. The most common adverse reactions is injection site reactions. Lenacapavir is substrate of cytochrome P450 (CYP) 3A enzymes, P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferases 1A1 (UGT1A1) and moderate inhibitor of CYP3A. Drug-drug interactions should be concerned when use lenacapavir in combination with other drugs. For pediatric and elderly populations, efficacy and safety data are limited.
Schlagwörter
Zitieren
APA
Wararit, C. (2024). Lenacapavir: new drug for the treatment of multidrug-resistant HIV infection. Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci). https://doi.org/10.14456/ijps.2024.7
Vancouver
Wararit C. Lenacapavir: new drug for the treatment of multidrug-resistant HIV infection. Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci). 2024. doi:10.14456/ijps.2024.7
BibTeX
@article{Wararit2024,
author = {Wararit, Chatchai},
title = {Lenacapavir: new drug for the treatment of multidrug-resistant HIV infection},
journal = {Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)},
year = {2024},
doi = {10.14456/ijps.2024.7}
}
EUVIMED